Blocking the survival of the nastiest by HSP90 inhibition

Paul Workman; Paul A. Clarke; Bissan Al-Lazikani

doi:10.18632/oncotarget.6971

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Blocking the survival of the nastiest by HSP90 inhibition

Paul Workman _, Paul A. Clarke and Bissan Al-Lazikani

PDF | HTML | How to cite

Oncotarget. 2016; 7:3658-3661. https://doi.org/10.18632/oncotarget.6971

Metrics: PDF 2358 views | HTML 3227 views | ?

Abstract

Paul Workman1, Paul A. Clarke1 and Bissan Al-Lazikani1

1 Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK

Correspondence to:

Paul Workman, email:

Keywords: HSP90

Received: November 20, 2015 Accepted: January 21, 2016 Published: January 21, 2016

Abstract

It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance – knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6971

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Blocking the survival of the nastiest by HSP90 inhibition

Abstract